The Green Cross Corporation

Asahi Glass Company, Limited

Other

Nissan Chemical Industries Limited

Yoshitomi Pharmaceutical Industries, Ltd.

Norifumi Nakamura

Yoshihisa Inoue

Hajime Ebisu

Takashi Okazoe

Yoshitomi Morizawa

Takehiro Okada

Arata Yasuda

Masahiro Eda

Jun Sasaki

Teruaki Imada

Hideaki Kido

Naomichi Ishida

Feng Wang

Ruriko Ikegawa

Chikara Fukaya

Kazuhiro Maeda

Atsuyuki Ashimori

Masanori Sugiura

Toru Kawamura

Fumio Mori

Kazutaka Hayashi

Yasumi Uchida

Yoshiji Kubo

Tomohiro Yoshida

Hiroshi Sakashita

Maki Goda

Shinichiro Ono

Keigo Kosaka

Sumio Matzno

Miyuki Eiraku

Mitsuyoshi Hihara

Tadahiro Takemoto

Keizo Tanikawa

Masahiro Watanabe

Nobutomo Tsuruzoe

Koichi Yamanouchi

Toshiaki Akira

Takeshi Uchida

Hiroshi Shinyama

Minori Okita

Masahide Nakajima

Shuzhong Wang

Mizuo Miyazaki

Yasuhiro Egi

Mamoru Koyama

Tomoyuki Maruyama

Katsumi Yamanaga

Yuji Narita

Tomoko Ito

Therapeutic agent for spinal canal stenosis

An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I)

Angiogenesis promoters and angiogenesis potentiators

Preventives/remedies for muscle tissue degenerations

Agent for prophylaxis and treatment of thromboxane A.sub.2 -mediated

Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.

Process for producing 2-(carboxyphenyl)-4-quinolinecarboxylic acid

A novel carboxylic acid compound having a condensed ring; which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.

Carboxylic acid compound having condensed ring, salt thereof and

A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.

Quinoline compounds

Pharmaceutical use of dihydropyridine derivative

An isoindazole compound of the formula (1) or a salt thereof; a method for the production thereof; and pharmaceutical use of the compound and a salt thereof, particularly as an angiotensin II antagonist and as an agent for the prophylaxis and treatment of circulatory diseases (particularly hypertension and heart failure); ##STR1## wherein Q is a heterocyclic derivative of the formula (2) or (3) ##STR2## wherein other symbols of the above formulas are as defined in the Specification. The compound and its salt show superior angiotensin II antagonism and are low toxic. Accordingly, they are useful as angiotensin II antagonists for the treatment or prophylaxis of angiotensin II-mediated diseases such as circulatory diseases of hypertension (e.g. essential hypertension, renal hypertension) and heart failure.

Isoindazole compound

An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --NR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3 or --NHSO.sub.2 R.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; an optical isomer thereof or art acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.

Aminopyridine compounds

An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.O, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --CN, --NR.sub.3 R.sub.4, --CONR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3, --NHSO.sub.2 R.sub.3 or --SR.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; or an acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.

Growing community of inventors

Osaka, Japan

Norifumi Nakamura